Proteome-based plasma markers of brain amyloid-β deposition in non-demented older individuals.
暂无分享,去创建一个
L. Ferrucci | S. Resnick | Y. An | S. Lovestone | R. Tripaldi | D. Wong | J. Sojkova | Yun Zhou | M. Thambisetty | A. Hye | S. Lynham | Anna M. Kinsey | J. Riddoch-Contreras | James Campbell | Romina Tripaldi | Abdul Hye
[1] Susan M Resnick,et al. Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. , 2010, Archives of general psychiatry.
[2] M. Citron. Alzheimer's disease: strategies for disease modification , 2010, Nature Reviews Drug Discovery.
[3] L. Ferrucci,et al. Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB , 2010, Neurology.
[4] H. Hampel,et al. Blood-based biomarkers of microvascular pathology in Alzheimer’s disease , 2010, Experimental Gerontology.
[5] A. Fagan,et al. APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal aging , 2010, Annals of neurology.
[6] Dominique Drouin,et al. Toward an Alzheimer's disease diagnosis via high-resolution blood gene expression , 2010, Alzheimer's & Dementia.
[7] Carol Brayne,et al. Age, neuropathology, and dementia. , 2009, The New England journal of medicine.
[8] Katharina Buerger,et al. Biological Marker Candidates of Alzheimer's Disease in Blood, Plasma, and Serum , 2009, CNS neuroscience & therapeutics.
[9] Mark A Mintun,et al. Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. , 2009, Archives of neurology.
[10] Denise C. Park,et al. Beta-Amyloid Deposition and the Aging Brain , 2009, Neuropsychology Review.
[11] P. Sachdev,et al. Plasma biomarkers for mild cognitive impairment and Alzheimer's disease , 2009, Brain Research Reviews.
[12] Monique Breteler,et al. Identifying Early Markers of Alzheimer's Disease using Quantitative Multiplex Proteomic Immunoassay Panels , 2009, Annals of the New York Academy of Sciences.
[13] W. M. van der Flier,et al. Parental history of Alzheimer disease associated with lower plasma apolipoprotein E levels , 2009, Neurology.
[14] D. Holtzman,et al. The Role of Apolipoprotein E in Alzheimer's Disease , 2009, Neuron.
[15] Keith A. Johnson,et al. Amyloid Deposition Is Associated with Impaired Default Network Function in Older Persons without Dementia , 2009, Neuron.
[16] G. Frisoni,et al. In vivo mapping of amyloid toxicity in Alzheimer disease , 2009, Neurology.
[17] G. Alexander,et al. Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease , 2009, Proceedings of the National Academy of Sciences.
[18] C. Dobson,et al. α2-Macroglobulin and Haptoglobin Suppress Amyloid Formation by Interacting with Prefibrillar Protein Species* , 2009, Journal of Biological Chemistry.
[19] D. Loewenstein,et al. Medial temporal lobe atrophy on MRI scans and the diagnosis of Alzheimer disease , 2008, Neurology.
[20] D. Lairon,et al. The effect of apoE genotype and sex on ApoE plasma concentration is determined by dietary fat in healthy subjects , 2008, British Journal of Nutrition.
[21] Susan M Resnick,et al. Longitudinal Cerebral Blood Flow and Amyloid Deposition: An Emerging Pattern? , 2008, Journal of Nuclear Medicine.
[22] Eileen Daly,et al. Proteome-based identification of plasma proteins associated with hippocampal metabolism in early Alzheimer’s disease , 2008, Journal of Neurology.
[23] T. Comery,et al. Enhanced clearance of Aβ in brain by sustaining the plasmin proteolysis cascade , 2008, Proceedings of the National Academy of Sciences.
[24] R. Tibshirani,et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins , 2007, Nature Medicine.
[25] Agneta Nordberg,et al. Amyloid imaging in Alzheimer's disease , 2007, Neuropsychologia.
[26] Yun Zhou,et al. Using a reference tissue model with spatial constraint to quantify [11C]Pittsburgh compound B PET for early diagnosis of Alzheimer's disease , 2007, NeuroImage.
[27] Rebecca F. Halperin,et al. A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease. , 2007, The Journal of clinical psychiatry.
[28] S. Lovestone,et al. Proteome-based plasma biomarkers for Alzheimer's disease. , 2006, Brain : a journal of neurology.
[29] P. Herrling,et al. List of Drugs in Development for Neurodegenerative Diseases , 2006, Neurodegenerative Diseases.
[30] S. DeKosky,et al. Kinetic Modeling of Amyloid Binding in Humans using PET Imaging and Pittsburgh Compound-B , 2005, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[31] J. Melchor,et al. Tissue plasminogen activator in central nervous system physiology and pathology , 2005, Thrombosis and Haemostasis.
[32] Ross Prentice,et al. Research issues and strategies for genomic and proteomic biomarker discovery and validation: a statistical perspective. , 2004, Pharmacogenomics.
[33] P. Herrling,et al. List of Drugs in Development for Neurodegenerative Diseases , 2004, Neurodegenerative Diseases.
[34] Bruce J Aronow,et al. ApoE and Clusterin Cooperatively Suppress Aβ Levels and Deposition Evidence that ApoE Regulates Extracellular Aβ Metabolism In Vivo , 2004, Neuron.
[35] Paul J. Laurienti,et al. An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets , 2003, NeuroImage.
[36] Trey Sunderland,et al. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. , 2003, JAMA.
[37] J. Hardy,et al. The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .
[38] Harald Hampel,et al. CSF total tau, Aβ42 and phosphorylated tau protein as biomarkers for Alzheimer’s disease , 2001, Molecular Neurobiology.
[39] G. Alexander,et al. Declining brain activity in cognitively normal apolipoprotein E ɛ4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[40] J. Mazziotta,et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[41] S. Resnick,et al. One-year age changes in MRI brain volumes in older adults. , 2000, Cerebral cortex.
[42] P. de Knijff,et al. ApoE polymorphism accounts for only part of the genetic variation in quantitative ApoE levels , 2000, Genetic epidemiology.
[43] G. Siest,et al. Apolipoprotein E Polymorphism and Serum Concentration in Alzheimer's Disease in Nine European Centres: the ApoEurope Study , 2000, Clinical chemistry and laboratory medicine.
[44] H. Braak,et al. Evolution of the neuropathology of Alzheimer's disease , 1996, Acta neurologica Scandinavica. Supplementum.
[45] L. Tiret,et al. Polymorphisms of the apolipoprotein B and E genes and their relationship to plasma lipid variables in healthy Chinese men , 1993, Human Genetics.
[46] D. T. Vernier,et al. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. , 1990, Journal of lipid research.
[47] Mark R. Wilson,et al. Extracellular chaperones modulate the effects of Alzheimer’s patient cerebrospinal fluid on Aβ1-42 toxicity and uptake , 2009, Cell Stress and Chaperones.
[48] D. Holtzman. In vivo effects of apoE and clusterin on amyloid-β metabolism and neuropathology , 2007, Journal of Molecular Neuroscience.
[49] D. Holtzman. In vivo effects of ApoE and clusterin on amyloid-beta metabolism and neuropathology. , 2004, Journal of molecular neuroscience : MN.
[50] J. Yesavage,et al. Identification of Fast and Slow Decliners in Alzheimer Disease: A Different Approach , 1995, Alzheimer disease and associated disorders.
[51] B. Kowalski,et al. Partial least-squares regression: a tutorial , 1986 .
[52] A. Nappi,et al. Alzheimer ' s Disease : Cell-Specific Pathology Isolates the Hippocampal Formation , 2022 .